Accuray (NASDAQ:ARAY) Bolsa

Accuray

Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.

Accuray Inc

<h3>Gainers</h3>
<ul>
<li><strong>Phathom Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>) stock rose 85.8% to $8.71 during Friday's regular session. The company's market cap stands at $606.9 million. </li>
<li><strong>Know Labs</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) shares rose 54.86% to $0.79. The market value of their outstanding shares is at $5.9 million. </li>
<li><strong>Bluejay Diagnostics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) shares rose 48.68% to $2.26. The market value of their outstanding shares is at $3.3 million. </li>
<li><strong>China SXT Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) stock moved upwards by 39.16% to $1.86. The company's market cap stands at $48.5 million. </li>
<li><strong>BioSig Technologies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock moved upwards by 38.76% to $7.96. The market value of their outstanding shares is at $217.4 million. </li>
<li><strong>NuCana</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock moved upwards by 29.87% to $0.05. As per the news, the Q1 earnings report came out 4 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Vera Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) shares fell 29.0% to $21.74 during Friday's regular session. The market value of their outstanding shares is at $1.3 billion. </li>
<li><strong>Scinai Immunotherapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) stock fell 24.62% to $2.45. The market value of their outstanding shares is at $2.2 million. </li>
<li><strong>Accuray</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) shares declined by 15.17% to $1.29. The market value of their outstanding shares is at $132.8 million. </li>
<li><strong>Cyclacel Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares decreased by 15.1% to $0.51. The company's market cap stands at $12.2 million. </li>
<li><strong>Evoke Pharma</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares fell 13.4% to $3.0. The company's market cap stands at $4.4 million. </li>
<li><strong>Nuwellis</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock declined by 13.39% to $0.53. The market value of their outstanding shares is at $2.3 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Movers

ARAY

BJDX

BSGM

CYCC

EVOK

NCNA

NUWE

PHAT

SCNI

SXTC

VERA

12 Health Care Stocks Moving In Friday's Intraday Session

WIIM

Accuray shares are trading lower after the company announced a convertible notes exchange and refinancing of its existing credit facilities.

<h3>Gainers</h3>
<ul>
<li><strong>Bluejay Diagnostics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock rose 55.3% to $2.36 during Friday's pre-market session. The market value of their outstanding shares is at $3.5 million. </li>
<li><strong>Venus Concept</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares increased by 50.62% to $3.6. The company's market cap stands at $5.1 million. </li>
<li><strong>Eyenovia</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock rose 39.79% to $4.39. The market value of their outstanding shares is at $12.6 million. </li>
<li><strong>Regencell Bioscience</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock moved upwards by 23.2% to $770.0. The company's market cap stands at $10.0 billion. </li>
<li><strong>Helius Medical Tech</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock moved upwards by 17.54% to $1.34. </li>
<li><strong>Akanda</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) stock moved upwards by 14.12% to $1.45. The market value of their outstanding shares is at $3.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Vera Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) stock decreased by 29.8% to $21.5 during Friday's pre-market session. The market value of their outstanding shares is at $1.3 billion. </li>
<li><strong>Accuray</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) shares declined by 22.37% to $1.18. The company's market cap stands at $121.5 million. </li>
<li><strong>Liminatus Pharma</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) shares fell 17.12% to $20.39. The company's market cap stands at $530.4 million. </li>
<li><strong>Scinai Immunotherapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) shares declined by 13.24% to $2.82. The company's market cap stands at $2.6 million. </li>
<li><strong>Durect</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) shares fell 11.01% to $0.48. The market value of their outstanding shares is at $14.8 million. </li>
<li><strong>NewGenIvf Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares fell 10.44% to $2.06. The company's market cap stands at $1.5 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AKAN

DRRX

EYEN

HSDT

LIMN

NIVF

VERO

12 Health Care Stocks Moving In Friday's Pre-Market Session

News

Accuray To Exchange $82M Of 3.75% Convertible Notes For 8.88M Shares And $68.6M Cash In Debt Reduction Deal Closing June 11

Accuray Announces That New Data Presented At The European Society For Radiotherapy And Oncology Meeting Reinforces The Benefits Of The Company's CyberKnife System In The Treatment Of Prostate Cancer At Multiple Stages Of The Cancer Journey

Biotech

General

Accuray Reports First SRS/SBRT Patient Treatments in Austria With the CyberKnife System

Accuray shares are trading lower after the company reported Q3 financial results and cut its FY25 sales guidance.

<p>Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) lowers FY2025 sales outlook from $463.00 million-$475.00 million to $452.00 million-$460.00 million vs $468.30 million estimate.</p>


Guidance

Accuray Lowers FY2025 Sales Guidance from $463.00M-$475.00M to $452.00M-$460.00M vs $468.30M Est

<p>Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.05) by 80 percent. This is a 83.33 percent increase over losses of $(0.06) per share from the same period last year.  The company reported quarterly sales of $113.24 million which beat the analyst consensus estimate of $101.53 million by 11.53 percent.  This is a 11.98 percent increase over sales of $101.13 million the same period last year.</p>


Earnings

Earnings Beats

Accuray Q3 EPS $(0.01) Beats $(0.05) Estimate, Sales $113.24M Beat $101.53M Estimate

AEIS

ALGN

ALKT

AMCR

ANSS

ATNI

AWRE

BLCO

BLFY

BLKB

BXMT

CACC

CAKE

CDNA

CFLT

CGNX

CHEF

CHRW

CLMB

CMPR

CNMD

CNXN

COCO

COKE

CPSH

CSLR

CSTM

CTOS

CTSH

CVEO

CWAN

CWEN

DFIN

EBAY

ENVX

EQIX

EQNR

ETSY

EXTR

FCPT

FFWM

FINW

FMBH

FORM

FTAI

GEHC

GKOS

GNRC

GRBK

GRMN

GTES

Earnings Scheduled For April 30, 2025

<p>Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) is preparing to release its quarterly earnings on Wednesday, 2025-04-30. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Accuray to report an <strong>earnings per share</strong> (EPS) of $-0.05.</p>
<p>Accuray bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Past Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS beat by $0.06, leading to a 8.03% increase in the share price on the subsequent day.</p>
<p>Here's a look at Accuray's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.04</td>
<td>-0.05</td>
<td>0.03</td>
<td>-0.01</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.02</td>
<td>-0.04</td>
<td>0.03</td>
<td>-0.06</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>8.0%</td>
<td>3.0%</td>
<td>52.0%</td>
<td>-28.999999999999996%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745960506_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Accuray were trading at $1.61 as of April 28. Over the last 52-week period, shares are down 25.35%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/ARAY/earnings"><strong>To track all earnings releases for Accuray visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Insights Ahead: Accuray's Quarterly Earnings

<p>SRS and SBRT are non-surgical procedures that deliver precisely targeted doses of radiotherapy, typically in one to five treatment sessions, with the goal of ablating (destroying) the tumor or lesion. To achieve the accuracy and precision required, the CyberKnife System uses image guidance during treatment, and leverages potentially 1,000 different beam angles targeting the tumor as well as Synchrony&#xAE; adaptive delivery, which adjusts the aim of the beam in real time to correct for tumor or patient motion.</p>
<p>"The studies presented at this year's Radiosurgery Society meeting underscore both the long-term efficacy and expanding applications of the CyberKnife System. Whether treating benign tumors like vestibular schwannoma or managing complex conditions such as spinal metastases and trigeminal neuralgia, the common thread is the need for precise, highly targeted radiation delivery — a hallmark of the CyberKnife System. These new data not only reinforce its value in central nervous system treatments but also add to the growing body of evidence supporting its role in improving both the quality and longevity of patients' lives," said Seth Blacksburg, M.D., MBA, Chief Medical Officer at Accuray.</p>
<p>RSS CyberKnife System Study Highlights: Advancing and Expanding Patient Care</p>
<p><strong>25-Year Data Supports the Use of the CyberKnife System to Treat Vestibular Schwannoma (VS)</strong></p>
<ul>
<li>25-year data were reported for patients in a single institution study retrospectively evaluating SRS for the treatment of VS (also known as acoustic neuroma) using the CyberKnife System. A non-cancerous, usually slow-growing brain tumor, VS can cause hearing loss, ringing in the ear, and dizziness or loss of balance. The study demonstrated treatment with the system provides sustained local tumor control and long-term efficacy. At 25 years, the local control rate was 89.3 percent and overall survival was 97.1 percent 2.</li>
</ul>
<p><strong>Clinical Innovation Facilitates Treatment of Challenging Condition Using the CyberKnife System</strong></p>
<ul>
<li>A study evaluated the safety and efficacy of donut-shaped circumferential stereotactic body radiation therapy (SBRT) delivered using the CyberKnife System for the treatment of spinal metastases. This treatment technique is designed to target the spinal column while avoiding the spinal cord. High doses of radiation delivered to the spinal cord can result in serious complications, such as radiation myelopathy, causing injury or paralysis. Study investigators concluded, "Donut-shaped circumferential CyberKnife SBRT is a safe and effective treatment for spinal metastases, achieving high local tumor control with minimal radiation-induced complications, including myelopathy&nbsp;3."</li>
</ul>
<p><strong>CyberKnife System Expands Treatment Options for Patients with Painful Neurological Conditions</strong><br /><br />Trigeminal neuralgia and occipital condyle metastasis are rare conditions often causing excruciating pain that may impact all aspects of patients' daily life.</p>
<ul>
<li>A study of elderly patients (aged 80 to 100 years) with trigeminal neuralgia found that radiosurgery delivered using the CyberKnife System provides excellent outcomes. Pain improved or disappeared in 90 percent of those evaluated and only three percent developed paresthesia – a sensation of tingling, "pins and needles" or numbness – considered bothersome. Data indicate radiosurgery provides an option for a patient population that may have limited choices because health issues preclude surgery or they are unresponsive to medication4.</li>
<li>An evaluation of SRS for occipital condyle metastasis (OCM) using the CyberKnife System found the treatment offers significant pain relief, excellent local control rates and improvement in neurological symptoms. A 93.8 percent local tumor control rate was achieved over three years. Of patients who reported symptoms, 87.5 percent experienced pain relief. Study authors concluded, "This non-invasive therapy provides a valuable alternative to surgery, potentially enhancing the quality of life for patients with limited treatment options due to this challenging condition5."</li>
</ul>


Health Care

Accuray Announced That New Data On The Clinical Use Of The CyberKnife System Reinforce The Device's Broad-based Radiation Treatment Capabilities For Central Nervous System Tumors

Accuray shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 sales guidance above estimates.

<p><strong>Accuray</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) released its Q2 earnings on Wednesday, February 5, 2025 at 04:05 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>Accuray beat estimated earnings by 150.0%, reporting an EPS of $0.02 versus an estimate of $-0.04.</p>
<p>Revenue was up $8.94 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>The company beat on EPS by $0.01 in the last quarter, resulting in a 3.0% increase share price change the following day.</p>
<p>Here's a look at Accuray's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.05</td>
<td>0.03</td>
<td>-0.01</td>
<td>-0.05</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.04</td>
<td>0.03</td>
<td>-0.06</td>
<td>-0.10</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>97.55M</td>
<td>121.51M</td>
<td>113.65M</td>
<td>106.67M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>101.55M</td>
<td>134.29M</td>
<td>101.13M</td>
<td>107.24M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Accuray <a href="https://www.benzinga.com/quote/ARAY/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Accuray Q2 Earnings Assessment

<p><strong>Accuray</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) announced its Q2 earnings on Wednesday, February 5, 2025 at 04:05 PM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>Accuray beat estimated earnings by 150.0%, reporting an EPS of $0.02 versus an estimate of $-0.04.</p>
<p>Revenue was up $8.94 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company beat on EPS by $0.01 which was followed by a 3.0% increase in the share price the next day.</p>
<p>Here's a look at Accuray's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.05</td>
<td>0.03</td>
<td>-0.01</td>
<td>-0.05</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.04</td>
<td>0.03</td>
<td>-0.06</td>
<td>-0.10</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>97.55M</td>
<td>121.51M</td>
<td>113.65M</td>
<td>106.67M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>101.55M</td>
<td>134.29M</td>
<td>101.13M</td>
<td>107.24M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Accuray <a href="https://www.benzinga.com/quote/ARAY/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Accuray Q2 Earnings Report: What Investors Need to Know

<p><strong>Accuray</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) released its Q2 earnings on Wednesday, February 5, 2025 at 04:05 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>Accuray beat estimated earnings by 150.0%, reporting an EPS of $0.02 versus an estimate of $-0.04.</p>
<p>Revenue was up $8.94 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the previous quarter, the company beat on EPS by $0.01, leading to a 3.0% increase share price change the next day.</p>
<p>Here's a look at Accuray's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.05</td>
<td>0.03</td>
<td>-0.01</td>
<td>-0.05</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.04</td>
<td>0.03</td>
<td>-0.06</td>
<td>-0.10</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>97.55M</td>
<td>121.51M</td>
<td>113.65M</td>
<td>106.67M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>101.55M</td>
<td>134.29M</td>
<td>101.13M</td>
<td>107.24M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Accuray <a href="https://www.benzinga.com/quote/ARAY/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Accuray Q2 Earnings Summary & Key Takeaways

<p><strong>Accuray</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) just disclosed its Q2 earnings on Wednesday, February 5, 2025 at 04:05 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Accuray beat estimated earnings by 150.0%, reporting an EPS of $0.02 versus an estimate of $-0.04.</p>
<p>Revenue was up $8.94 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>During the previous quarter, the company beat on EPS by $0.01, leading to a 3.0% increase share price change the next day.</p>
<p>Here's a look at Accuray's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.05</td>
<td>0.03</td>
<td>-0.01</td>
<td>-0.05</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.04</td>
<td>0.03</td>
<td>-0.06</td>
<td>-0.10</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>97.55M</td>
<td>121.51M</td>
<td>113.65M</td>
<td>106.67M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>101.55M</td>
<td>134.29M</td>
<td>101.13M</td>
<td>107.24M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Accuray <a href="https://www.benzinga.com/quote/ARAY/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings Summary: Accuray Q2

<p>Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) raises FY2025 sales outlook from $462.00 million-472.00 million to $463.00 million-475.00 million vs $466.89 million estimate.</p>


Accuray Raises FY2025 Sales Guidance from $462.00M-472.00M to $463.00M-475.00M vs $466.89M Est

<p>Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.04) by 150 percent. This is a 120 percent increase over losses of $(0.10) per share from the same period last year.  The company reported quarterly sales of $116.17 million which beat the analyst consensus estimate of $110.36 million by 5.27 percent.  This is a 8.33 percent increase over sales of $107.24 million the same period last year.</p>


Accuray Q2 EPS $0.02 Beats $(0.04) Estimate, Sales $116.17M Beat $110.36M Estimate

AMSC

AOSL

APPS

ARCC

ARES

ASGN

ASYS

AZTA

BARK

BLBD

BSBR

CENT

CENTA

CMRE

COHR

CPAY

CPRI

CRTO

CSGS

CTVA

DGII

DLHC

ENSG

EZPW

GEOS

HOLX

ITUB

KMPR

LFVN

LSAK

LUCK

LVWR

MSTR

MTRX

MUSA

NOTV

NTGR

NVST

NWSA

ODFL

ORLY

PAHC

PFGC

Earnings Scheduled For February 5, 2025

Press Releases

Accuray Announces First 100 Patient Treatment Regimens Completed in China Using the Tomo® C Radiation Treatment Delivery System, a CNNC-Accuray Joint Venture Product

Accuray Reports Strong Fiscal 2025 Second Quarter Financial Results & Raises Guidance

Accuray to Participate at 37th Annual Roth Conference

Accuray CyberKnife® Platform Featured in New Studies Showcasing its Benefits in Central Nervous System Tumors Presented at Radiosurgery Society Scientific Meeting

Accuray to Report Third Quarter Fiscal 2025 Financial Results on April 30, 2025

Accuray Reports Fiscal 2025 Third Quarter Financial Results

Accuray Announces First SRS/SBRT Patient Treatments in Austria With the CyberKnife® System

Accuray Showcases New Long-Term Data¹ on Benefits of 5 Session Radiotherapy Treatment for Men with Prostate Cancer at ESTRO 2025

Accuray to Participate in the Jefferies Global Healthcare Conference 2025

Contracts

Accuray Announces Convertible Notes Exchange and Refinancing of Existing Credit Facilities

Comments

Accuray

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL